First treatment for rare brain cancer in 20 years lands on PBS
A new drug called vorasdienib has been listed on Australia's Pharmaceutical Benefits Scheme (PBS) to treat rare, incurable brain cancers. The listing significantly reduces the cost for patients, providing access to a treatment that can slow disease progression.
Why it matters
This represents a major medical breakthrough for patients with specific genetic mutations, offering life-extending treatment at an affordable price point.
- 9.59am . First published at 1.42am
shares Share article The first breakthrough treatment for a rare, incurable brain cancer in more than 20 years will be listed on the PBS this week, saving patients tens of thousands of dollars.
The drug vorasdienib, sold as Voranigo, will be listed on the subsidised scheme for people living with IDH-mutant astrocytoma or oligodendroglioma.
A new drug for a rare brain cancer has been listed on the PBS. Mohammed Haneefa Nizamudeen
These brain tumours, while rare, are the most common malignant primary brain tumours in adults under 50, and affect an estimated 3230 Australians, according to Voranigo manufacturers Servier.
Patients are typically diagnosed between the ages of 20 and 45, with symptoms escalating over many years including seizures, cognitive changes, physical disability, and loss of independence.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in